These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29702525)

  • 1. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis.
    He D; Chatterjee A; Fan X; Wang S; Eggener S; Yousuf A; Antic T; Oto A; Karczmar GS
    Invest Radiol; 2018 Oct; 53(10):609-615. PubMed ID: 29702525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer.
    Chatterjee A; He D; Fan X; Wang S; Szasz T; Yousuf A; Pineda F; Antic T; Mathew M; Karczmar GS; Oto A
    Acad Radiol; 2018 Mar; 25(3):349-358. PubMed ID: 29167070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of double inversion recovery magnetic resonance imaging (DIR-MRI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in detection of prostate cancer: A pilot study.
    Onwuharine EN; Clark AJ
    Radiography (Lond); 2020 Aug; 26(3):234-239. PubMed ID: 32052752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation.
    Fennessy FM; Fedorov A; Penzkofer T; Kim KW; Hirsch MS; Vangel MG; Masry P; Flood TA; Chang MC; Tempany CM; Mulkern RV; Gupta SN
    Magn Reson Imaging; 2015 Sep; 33(7):886-94. PubMed ID: 25683515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
    Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
    J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study.
    Beer L; Polanec SH; Baltzer PAT; Schatzl G; Georg D; Schestak C; Dutschke A; Herrmann H; Mazal P; Brendel AK; Shariat SF; Ringl H; Helbich TH; Apfaltrer P
    PLoS One; 2019; 14(12):e0225673. PubMed ID: 31856177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer?
    Cristel G; Esposito A; Briganti A; Damascelli A; Brembilla G; Freschi M; Ambrosi A; Montorsi F; Del Maschio A; De Cobelli F
    Clin Radiol; 2019 Apr; 74(4):259-267. PubMed ID: 30739715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI.
    Wang S; Fan X; Zhang Y; Medved M; He D; Yousuf A; Jamison E; Oto A; Karczmar GS
    Tomography; 2019 Jun; 5(2):260-265. PubMed ID: 31245547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
    Sung YS; Kwon HJ; Park BW; Cho G; Lee CK; Cho KS; Kim JK
    AJR Am J Roentgenol; 2011 Nov; 197(5):1122-9. PubMed ID: 22021504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
    Baur ADJ; Schwabe J; Rogasch J; Maxeiner A; Penzkofer T; Stephan C; Rudl M; Hamm B; Jung EM; Fischer T
    Eur Radiol; 2018 May; 28(5):1949-1960. PubMed ID: 29238867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
    Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
    Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation between subcentimeter carcinomas and benign lesions using kinetic parameters derived from ultrafast dynamic contrast-enhanced breast MRI.
    Onishi N; Sadinski M; Gibbs P; Gallagher KM; Hughes MC; Ko ES; Dashevsky BZ; Shanbhag DD; Fung MM; Hunt TM; Martinez DF; Shukla-Dave A; Morris EA; Sutton EJ
    Eur Radiol; 2020 Feb; 30(2):756-766. PubMed ID: 31468162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?
    Lotte R; Lafourcade A; Mozer P; Conort P; Barret E; Comperat E; Ezziane M; de Guibert PJ; Tavolaro S; Belin L; Boudghene F; Lucidarme O; Renard-Penna R
    Eur Radiol; 2018 Sep; 28(9):3760-3769. PubMed ID: 29633004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer.
    Eyal E; Bloch BN; Rofsky NM; Furman-Haran E; Genega EM; Lenkinski RE; Degani H
    Invest Radiol; 2010 Apr; 45(4):174-81. PubMed ID: 20177391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced MRI of the prostate with high spatiotemporal resolution using compressed sensing, parallel imaging, and continuous golden-angle radial sampling: preliminary experience.
    Rosenkrantz AB; Geppert C; Grimm R; Block TK; Glielmi C; Feng L; Otazo R; Ream JM; Romolo MM; Taneja SS; Sodickson DK; Chandarana H
    J Magn Reson Imaging; 2015 May; 41(5):1365-73. PubMed ID: 24833417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of CAIPIRINHA-Dixon-TWIST-VIBE for dynamic contrast-enhanced MRI of the prostate.
    Othman AE; Martirosian P; Schraml C; Taron J; Weiss J; Bier G; Schwentner C; Nickel D; Bamberg F; Kramer U; Nikolaou K; Notohamiprodjo M
    Eur J Radiol; 2015 Nov; 84(11):2110-6. PubMed ID: 26321493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.